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Abstract
AIM: To assess how the application of different types 
of markers affects the tracking accuracy of CyberKnife’s.
METHODS: Fifteen patients were recruited and sub-
jected to the ultrasound-guided placement of markers. 
Two different type of needles 25 gauge (G) and 17 G 
containing two different fiducial marker, gold notched 
flexible anchor wire 0.28 mm × 10 mm (25 G needle) 
and gold cylindrical grain 1 mm × 4 mm (17 G), were 
used. Seven days after the procedure, a CyberKnife 
planning computed tomography (CT) for the simulation 
of radiation treatment was performed on all patients. 
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A binary CT score was assigned to the fiducial markers 
visualization. Also, the CT number was calculated for 
each fiducial and the values compared with a specific 
threshold.
RESULTS: For each patient from 1 to 5, intra-hepatic 
markers were placed (one in 2 patients, three in 8 
patients, four in 3 patients, and five in 2 patients). A 
total of 48 needles were used (thirty-two 17 G and 
sixteen 25 G) and 48 gold markers were placed (32 
Grain shaped markers and 16 Gold Anchor). The result 
showed that the CT visualization of the grain markers 
was better than the anchor markers (P  = 5 × 10 -9). 
Furthermore, the grain markers were shown to present 
minor late complications (P  = 3 × 10-6), and the best 
CT threshold number (P  = 0.0005). 
CONCLUSION: The study revealed that the Gold 
Anchor fiducial marker is correlated with a greater 
number of late minor complications and low visualization 
by the CT.
Key words: Robotic radiosurgery; Fiducial markers; 
Liver malignancies; CyberKnife; Radiation therapy; 
Stereotactic radiosurgery
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Core tip: Robotic radiosurgery can employ different 
systems for the localization of the neoplastic targets to 
treat. The purpose of this study is to assess how the 
application of different types of markers affects the 
tracking accuracy of CyberKnife’s. Fifteen patients have 
been recruited and analyzed for the study and two types 
of markers were used for the procedure. The computed 
tomography (CT) visualization of grain markers was 
better than anchor markers P  = 5 × 10-9. Grain markers 
presented minor late complications of P  = 3 × 10-6, and 
the best CT threshold number. The study revealed that 
the Gold Anchor fiducial marker is correlated with a 
greater number of late minor complication.
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INTRODUCTION
The stereotactic robotic radiosurgery is able to admi­
nister high­dose radiation that could reach any anatomic 
point with a sub­millimeter precision[1­4]. The high 
accuracy is achieved by the image­guidance system 
robotic technology and the dynamic tracking of targets, 
that remove the effect of breathing. The use of these 
techniques permits the CyberKnife system’s to hit the 
lesion with high­dose radiation and to safeguard the 
surrounding critical organs which could suffer irrever­
sible damage[5­13]. Robotic radiosurgery can employ 
different systems for the localization of the neoplastic 
targets to treat. In particular, for the treatment of the 
parenchymatous organ tumors, CyberKnife uses a 
localization system based on specific gold markers[14]. 
Various types of gold markers can be employed in 
relation to the characteristics of the lesion and the 
different technique of placement. In particular, the type 
of gold markers to use often depends on the choice of 
needles of different calibers and length. The choice of 
the needle is influenced by the type and site of the lesion 
to treat and its proximity to critical organs or vascular 
structures[15,16]. The physical characteristic (dimensions 
and length) of the gold markers strongly depends on the 
characteristics of the needle. The gold markers (Gold 
Anchor) contained in fine needle [25 gauge (G) and 22 
G] must be smaller in dimension and longer than those 
contained in larger needles. Markers contained in fine 
needles, in order to reach an appropriate density for a 
normal computed tomography (CT) number and to be 
correctly recognized by the CyberKnife system, must 
assume a correct array in the parenchyma, when they 
are inserted. In fact, they have the advantage of being 
flexible and to curl up when they are pushed against 
the parenchyma tanks to the spindle and carried by the 
needle. Therefore, after their placement, the Gold Anchor 
reached some similar dimensions to those in grain and 
so, an appropriate density and a normal CT number. 
Therefore, if they are too crowded or shatter during 
their release, they do not achieve the proper density to 
have a normal CT number, and to be well recognized 
as a fiducial by the CyberKnife System. The markers 
(cylindrical markers) contained in larger gauge needles 
(17 G and 18 G) can not break and do not need to mass 
during their placement. Therefore they can not change 
their CT number (Figure 1)[17-21]. The placement of fi­
ducial markers may be burdened by complications due 
to puncture or related to the gold markers. For instance, 
the major complications related to the gold markers 
could be the migration of fiducials from the positioning 
site and the physical alterations of the markers, like 
marker not deployed or shattered, that may occur during 
or after placement[22-26]. These complications determine 
the lack of fiducials recognition by CyberKnife and result 
to failure in targeting the lesions that prevented the 
execution of the treatment[27,28].
The aim of this prospective pilot study was to 
assess, how the use of two different types of gold 
fiducial markers: Grain type and Anchor type, affects 
the accuracy of tracking by the CyberKnife System, and 
consequently, the therapeutic efficacy of the treatment 
of primary or metastatic liver malignancy. We also 
aimed to identify which type of fiducial can ensure better 
viability of the SRR.
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MATERIALS AND METHODS
Fifteen consecutive patients, who were scheduled to 
receive robotic radiotherapy treatment for primary or 
metastatic liver malignancy, were recruited for percu­
taneous ultrasonography (US)­guided placement of 
intra-hepatic fiducial markers, from March 2014 to 
June 2014 (Figure 1). A written informed consent 
was obtained from the patients. Two different types 
of needles, 25 G and 17 G containing two different 
fiducial markers, gold notched flexible anchor wire of 
0.28 mm × 10 mm (25 G needle) and gold cylindrical 
grain of 1 mm × 4 mm (17 G), were used. The needle 
type to use was selected according to the site of the 
lesion (deep or superficial liver lesion) and physical 
structure. The choice of the different fiducial markers 
depends mainly on the choice of the needle caliber. 
The number of fiducial markers to place was evaluated 
according to the acoustic window, the compliance 
of the patients and morphological characteristics of 
the lesions. The examination was performed by two 
expert ultrasonographers with the same echograph, 
ProSound Alfa7, (Hitachi­Aloka, Tokyo, Japan) with a 
3.75­7.5 MHz hemispheric sound technology (HST) 
91-30 Multi Frequency Convex Abdominal HST probe. 
Local anesthesia was achieved via the subcutaneous 
administration of 1% lidocaine. All the gold fiducial 
markers were placed with US­guidance through sub or 
intercostals access. After confirming that the needle tip 
had reached the target lesion, the fiducial marker was 
deployed, and then the needle was removed. We placed 
in each patient from 1 to 5 fiducial markers, and when 
at least two or more fiducials were placed, it was at a 
distance of about 1.5-2 cm apart, in a way to occupy 
the perpendicular edges of a cube containing the tumor 
inside. The Gold Anchor markers were always placed 
with the same technique to take advantage of their mass 
effect. Fiducial positioning was confirmed with ultrasound 
image. A marker was usually seen as a hyperechoic 
structure. The two different fiducial markers used were 
sonographycally undistinguishable (Figure 2). Technical 
success was defined when the implantation enables 
adequate treatment planning and CT simulation. Fiducial 
migration was defined as seed dislodgement outside 
the volume of the original injection site that is unusable 
for guiding stereotactic body radiation therapy (SBRT) 
as determined by planning CT. Clinical success was 
defined as the completion of SBRT. Seven days after the 
procedure, a CyberKnife planning CT for the simulation 
of radiation treatment was performed on all patients. 
733 June 18, 2016|Volume 8|Issue 17|WJH|www.wjgnet.com
A B
Figure 1  Types of gold fiducial markers. A: Twenty five gauge and 17 G needle and their gold markers: Grain cylindrical gold marker, 1 mm × 4 mm and flexible 
wire notched gold marker 0.28 mm × 10 mm, Gold Anchor Marker respectively; B: Grain cylindrical gold marker, 1 mm × 4 mm flexible wire notched gold marker 0.28 
mm × 10 mm, Gold Anchor marker after massing.
Figure 2  Ultrasonography-guided fiducial placement. The two different gold markers are sonographically undistinguishable. A: Needle delivering fiducial into a 
liver mass; B: Hyperechoic flexible wire notched gold marker, 0.28 mm × 10 mm, Gold Anchor marker (arrow) near a liver mass; C: Hyperechoic Grain cylindrical gold 
marker, 1 mm × 4 mm (arrow) near a liver mass.
A B C
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2 to metastasectomy and adjuvant therapy, 2 to neo-
adjuvant and adjuvant therapy and 1 to metastatec­
tomy without chemotherapy. Moreover among these 9 
patients, 7 developed new liver metastasis during or at
the end of the treatment, while 2 patients presented 
a metastatic recurrence. Only 2 patients of the 11 
affected by liver metastasis undergone treatment 
by chemotherapy and not surgery, one performed a 
palliative chemotherapy and the other performed an 
effective chemotherapy with failure of treatment. In 
the group of patients with primary hepatic neoplasm, 
patients affected by HCC and hepato­cholangiocar­
cinoma were treated by chemoembolization, while 
another one affected by cholangiocarcinoma undergone 
chemotherapy. Patients treated with chemoembolization 
showed relapse of neoplasm, while the patient treated 
with chemotherapy showed no response to the treat­
ment. In the group of patients with hepatic metastasis, 
8 of them have a single nodule, 2 of them have two 
nodules, and 1 has three nodules so the total of liver 
lesions treated was 15. These 15 liver lesions presented 
a maximum diameter between 2 to 4 cm. In the group 
of patients with primary liver lesions, 3 patients showed 
a single nodule and another one presented two nodules 
so the total primary lesion treated was 5. Four of these 
measured a maximum diameter from 2 to 4 cm and 
only one measured a maximum diameter over 4 cm. 2 
patients showed a moderate ascites at the moment of 
the procedure. The 20 liver lesions were localized into 
the Ⅶ liver segment (n = 7), Ⅵ liver segment (n = 3), 
Ⅷ segment (n = 3), Ⅴ segment (n = 1), Ⅳ segment (n 
= 1), Ⅲ segment (n = 1), between Ⅴ­Ⅵ segment (n 
= 1), between Ⅴ­Ⅵ­Ⅶ segments (n = 1) and between 
Ⅵ­Ⅶ segments (n = 2). Five lesions were localized 
close to vascular structures and 2 lesions close to critical 
organs. Considering the closeness of the critical organs 
or vascular structures and the patients’ compliance, 8 
patients undergone a combined placement of the two 
types of gold markers. Two patients presented severe 
compliance problems (panic attack), so they received 
only anchor markers (placed with fine needles). Five 
patients received only cylindrical grain markers. For each 
A binary CT score for the fiducial markers visualization 
was assigned (not visualized or poorly visualized = 0; 
well visualized = 1) (Figure 3). In the case of CT score 
of zero (0) which prevented treatment, we organized a 
series of multidisciplinary meetings (with regards to the 
procedure, the physician and the radiation oncologist 
responsible for the radiosurgery treatment) to achieve 
the correct radiological visualization of the fiducial 
marker. Moreover, for the execution of treatment with 
CyberKnife, it is necessary that each fiducial reaches 
a CT number above a specific threshold (CT number 
threshold). The CT number of the fiducial is assigned 
in an automated manner by the CyberKnife machine 
(Figure 4). Database construction and data analysis 
were performed using Office Excel 2007, XLSTAT 2016 
(microsoft) and SPSS for Windows (SPSS Inc., Chicago, 
United States). We examined the data with the use of 
appropriate parametric and non­parametric statistical 
tests (Student’s t­test two­tailed and a χ 2 test according 
to Fischer considering P < 0.05 as significant). A Lilliefors 
(Kolmogorov­Smirnov) test for normality has been 
previously performed. Statistical analysis was performed 
by Tommaso Gabbani, MD, and reviewed by Principal 
Investigator, Maria Marsico, MD.
RESULTS 
Fifteen consecutive patients (men: 9, women: 6, mean 
age: 72.9 years old, range: SD ± 7.9) who had already 
undergone percutaneous ultrasound­guided fiducial 
marker implantations for CyberKnife therapy were 
employed for this study. Eleven patients (8 males) pre-
sented liver metastasis from a note primary neoplasm 
(2 right colon carcinoma, 2 sigmoid carcinoma, 2 rectum 
carcinoma, 1 gastric carcinoma, 1 lung carcinoma, 1 ova­
ric carcinoma and 2 pancreatic carcinoma). Four patients 
(2 males) showed liver primary malignancy [2 hepa-
tocellular carcinoma (HCC), 1 cholangio­carcinoma, 1 
hepatic cholangio­carcinoma]. Among 11 patients who 
presented liver metastasis, 9 patients had previously
undergone radical surgery of primary neoplasm. Among 
these 9 patients, 4 had submitted to adjuvant therapy, 
Figure 3  Well visualized fiducial markers. A: CT displaying of Grain cylindrical gold marker, 1 mm × 4 mm. This marker exhibits good contrast on X-ray images with 
typical “star effects”; B: CT displaying types of flexible wire notched gold marker, 0.28 mm × 10 mm, Gold Anchor marker. This marker exhibits good contrast on X-ray 
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patient about 1 to 5 intra­hepatic markers were placed 
(one in 2 patients, three in 8 patients, four in 3 patients, 
and five in 2 patients). A total of 48 needles were used 
(thirty-two 17 G and sixteen 25 G) and 48 gold markers 
were placed (32 Grain shaped markers and 16 Gold 
Anchors). In 47 cases, the gold markers were placed 
through subcostal access and only in a single case with 
an inter-costal access. Every patient received a local 
anesthesia with lidocaine. All fiducials placement were 
sonographically confirmed right after the procedure. No 
patient presented any major complication related to the 
procedure. 
After the placement of markers, 14 patients under­
went the planning simulation CT scan to allow fiducials 
to settle. One patient did not perform the CT because 
of a complication related to the primary tumor (hepatic 
failure). Removing the latter patient who was excluded 
from the treatment for causes not correlated to the 
fiducial placement, the technical and clinical success 
rate was 100%. The CT scan revealed that 14 markers 
(11 Gold Anchors and 3 Grain shaped markers) showed 
late complications. Few markers showed more than one 
complications at the same time for a total of 27 com-
plications. Shattered markers (n = 2; 2 Gold Anchors), 
extra­hepatic migration (n = 4; 1 Gold Anchor and 3 
Grain markers), extra­hepatic migration and marker not 
visualized (n = 1; 1 Gold Anchor), intra-hepatic migration 
(n = 5; 5 Gold Anchors), not massed markers (n = 5; 5 
Gold Anchor). The Gold Anchor marker presented more 
frequent late minor complications (68.75% vs 9.375%, 
P = 3 × 10­6). Moreover, 38 markers were visualized 
with CT score = 1 and 10 markers with CT score = 0, 
the markers visualized with CT score = 0 were all Gold 
Anchors and we demonstrated that the CT subjective 
visualization of Grain shaped markers was significantly 
higher than the CT subjective visualization for Gold 
Patients affecting by liver malignancies were preventive selected by 
radiotherapists for treatment with stereotactic robotic radiosurgery
Preventive evaluation of CT images, blood chemistry and assumption of antiplatelet agents/
anticoagulants before percutaneous placement of fiducial markers by ultrasonographer
Ultrasound visualization of placed fiducial and patient observation 
in DH for at least 6 h. Discharge if absence of complication
CT score 1 (fiducial well visualized) 
and correct CT number
Execution of CT centering after 7 d by the procedure to 
evaluate possible late complications as fiducial migration and 
to evaluate their usability for the treatment
Using 17 G needle containing Grain cylindrical gold 
marker, 1 mm × 4 mm in case of patient compliance, 
patients obesity, presence of deep lesions and absence of 
criticalstructures near the lesion to treat
Using 25 G needle containing flexible wire notched gold 
marker, 0.28 mm × 10 mm, Gold Anchor marker. If 
presence of  superficial lesions, close critical structures near 
the lesion to treat and/or poor patient compliance
Treatment program
Ultrasound-guided percutaneous placement of fiducials using local anesthesia with Lidocaine
CT score 0 (fiducial not visualized or poorly 
visualized) and CT number below threshold 
assigned by CyberKnife machine
Organization of multidisciplinary meeting to 
achieve a correct radiological visualization 
of the fiducial marker
Figure 4  Flow chart of the study conducted tank to a prospective collection of data (compliance, demographic and clinic characteristics of the patients, 
liver lesions characteristics, type of needle and markers used, ultrasonographic and computed tomography visualization of fiducial markers, usability of 
the markers and immediate and late complications) and a retrospective statistical analysis. CT: Computed tomography.
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Anchor (100% vs 37.5%, P = 5 × 10­9). For 5 patient 
it was necessary to organize multidisciplinary meetings 
to identify the correct intra­hepatic localization of the 
markers visualized with CT score = 0. Finally, 5 markers 
showed a CT number below the threshold (5 Gold 
Anchors). The 5 markers with the CT number below the 
threshold were not recognized by the CyberKnife system 
and so were not used for the treatment (one marker 
not recognized for 5 patients). Forty­three markers 
(32 Grain shaped markers and 11 Gold Anchors) with 
regular CT number were recognized by CyberKnife 
system and were used for the treatment. The clinical 
success achieved was 89.6%. We demonstrated that the 
Gold Anchor marker is associated with a threshold below 
the CT number (31.25% vs 0%, P = 0.0005) that is not 
suitable for treatment. A total of 14 patients underwent 
radiosurgery treatment, only one patient was excluded 
because of a complication related to his primary tumor.
DISCUSSION 
The CyberKnife Robotic Radiosurgery System is a non­
surgical option for patients who have inoperable or 
surgically complex tumors or who may be looking for 
an alternative to surgery. It is an option in the case 
where no response and/or relapse is observed after 
chemotherapy and standard radiotherapy[29-31]. In our 
study, we compared the therapeutic usability of the two 
different gold fiducial markers for robotic radiosurgery 
treatment of primary and metastatic liver malignancies. 
We used the two different gold markers according to the 
necessity to either use 17 or 25 G needle, depending 
on the patient’s compliance, patient physical structure 
and the proximity of critical or vascular structures. This 
pilot trial demonstrate that the Anchor marker (0.28 
mm × 10 mm) is correlated with a greater number of 
late minor complications that results from a frequent 
association with a CT number below threshold and a 
low subjective CT visualization, resulting in a delay or a 
difficulty in starting the treatment. In our opinion, the 
use of the Gold Anchor marker should be limited to use 
of the 25 G needle and in combination with the other 
types of markers. Only few studies have compared 
the use of different fiducial in the terms of efficacy 
and complications[32,33]. Our study differs from others 
because it compares the two different types of gold 
fiducial markers in terms of usability for CyberKnife 
treatment. In our study, we identified some of the 
factors related to the type of fiducials (the Gold Anchor) 
that may prevent the treatment with CyberKnife. The 
identification and knowledge of these factors allows us 
to limit the use of Gold Anchor marker type, to specific 
cases and preferably, in combination with the other 
marker types, in order to reduce the tracking problems 
of CyberKnife. Infact, CyberKnife tracking problems 
are causes of increasing costs and delay in treatment 
execution. Contrary to what is shown in our study, other 
trials have demonstrated the advantage of Gold Anchor 
fiducial than the other types of fiducial markers for the 
treatment with CyberKnife. Nevertheless, in these other 
studies, inserting of the fiducial markers was executed 
by endoscopic ultrasonography technique to treat tumors 
of the pancreas and lung. Therefore, it is our opinion 
that the different techniques for positioning, and the 
different localization of the lesions may be the basis of 
the different results obtained in the study. Furthermore, 
we must consider the variable offered by the needle. 
The percutaneous placement of Gold Anchor (0.28 mm 
× 10 mm) occurred with the 25 G needle that originally 
contained the gold marker. In the cases of endoscopic 
ultrasound guided placement of fiducial gold markers (in 
particular, for treatment of pancreas lesion), the 25 G 
needle originally containing the marker, serves only as a 
carrier to put the fiducials inside the other needles (22 G 
or 19 G) usually used for the fiducial placement. The use 
of needles with a greater caliber (22 G and 19 G) and 
less flexibility than the 25 G needle, may facilitate the 
placement of Gold Anchor limiting the complications.
COMMENTS
Background
The treatment of liver malignancies has evolved over the years. Although 
surgery is the current standard treatment for localized surgically operable 
lesions. Alternative treatment approaches for unresectable liver metastasis 
and primary liver cancer include: Chemoembolization, radiofrequency ablation, 
cryotherapy, and the oral multikinase inhibitor sorafenib, chemotherapy and 
standard radiotherapy. The CyberKnife Robotic Radiosurgery System is a non-
surgical option for patients who have inoperable or surgically complex tumors 
or who may be looking for an alternative to surgery. It also provides an option 
in the case where no response and/or relapse is observed after standard 
treatment.
Research frontiers
Many points still remain unclear in literature to ameliorate the treatment by 
CyberKnife and a lot of them seem to correlate with the type of fiducial to be 
use, the technique of placement and the number of fiducial to use. Nowadays, 
there are many different types of gold fiducial markers with different dimensions, 
lengths and physical characteristics. Therefore, many other studies of fiducial 
comparison, like the authors’, should be conducted. This is necessary to identify 
the basis of compliance, demographic and clinical characteristics of the patients 
and liver lesions characteristics, the best type of fiducial and needle to use. 
Percutaneous fiducial marker placement could be under computed tomography 
(CT) fluoroscopic guidance or ultrasonographic (US) guidance. In this study, 
fiducial placement was entirely conducted under US guidance demonstrating a 
great safety and efficacy. Cost-effectiveness studies should also be conducted 
to compare the CT and the US percutaneous fiducial placement to identify 
the best method in the terms of cost-effectiveness. Nowadays, there is yet 
no consensus in literatures on the exact number of fiducials necessary to 
effectively perform the treatment with CyberKnife. Many studies define the 
technical success as the ability to place more of a fiducial near the tumor target 
before the treatment; other studies have resulted in higher clinical success 
placing a unique fiducial marker for patient. In this study, the authors also 
demonstrated a high clinical success from using one to five fiducial for each 
patient, in relation to which fiducials were really recognized and used by the 
CyberKnife system (fiducial with correct relegated CT number). Therefore, 
many studies should be conducted regarding the different analysis of tracking 
accuracy resulting from the use of a different number of fiducial for treatment. 
This is important to establish the best number of fiducials to use in terms of cost 
effectiveness.
Innovations and breakthroughs
The study differs from others because it compares the two different types of 
gold fiducial markers in terms of usability for CyberKnife treatment of liver 
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malignacies. The study also differs for describing other possible complications 
related to Gold Anchor - their wrong stacking and their break after the 
placement. In this study, the authors identified some factors related to the type 
of fiducial, (the Gold Anchor) that may prevent the treatment with CyberKnife. 
The identification and knowledge of these factors allows them to limit the use 
of Gold Anchor marker type, to specific cases and preferably in combination 
with other marker types, in order to reduce tracking problems of CyberKnife. In 
fact, CyberKnife tracking problems are causes of increasing costs and delay 
in treatment execution. Contrary to what is shown in the study, other trials 
have demonstrated the advantage of Gold Anchor fiducial over the other types 
of fiducial markers for the treatment with CyberKnife. Nevertheless, in these 
other studies, the inserting of fiducial markers was executed by endoscopic 
ultrasonography technique for treating tumors of the pancreas and lung. 
Therefore, it is the authors’ opinion that the different techniques of positioning, 
and the different localization of the lesions and the different needles (generally 
of higher caliber) used for the placement of Gold Anchor may be the basis of 
the different results obtained in this study.
Applications
In the authors’ opinion, the use of Gold Anchor marker type has to be limited 
to specific cases; in order to reduce tracking problems of CyberKnife treatment 
which is the major cause of increasing costs and delay in treatment execution. 
Therefore, the authors suggest that the use of the Gold Anchor marker should 
be limited to the necessity to use the 25 G needle and in combination with the 
other type of markers. In particular, the 25 G needle should be used in the case 
of low patient compliance, absence of obesity and in the presence of superficial 
lesions at critical structure near the liver lesions.
Terminology 
Stereotactic robotic radio surgery: Ability to dispense high doses of focused 
radiation in a minor number of fractions respect to the standard treatment (2-5 
vs 30-40). Ability to reach any point with anatomical precision and extreme 
sub-millimeter accuracy tanks to a target localization computerized system 
offered by CyberKnife system; CyberKnife: Robot with a complete autonomy 
characteristic with more than 1500 dispensing positions of X-ray; Variable 
diameter collimator; Synchrony Respiratory Tracking System to preserve 
the near organs from toxicity; Fiducial gold markers: Markers exploited by 
CyberKnife for the target localization in the treatment of parenchymatous 
organs lesions. This marker is made from gold, which makes it biocompatible 
and ensures it exhibits good contrast on X-ray images; CT number: A 
normalized value of the calculated X-ray absorption coefficient of a pixel (picture 
element) in a computed tomogram, expressed in Hounsfield units, where the 
CT number of air is -1000 and that of water is 0.
Peer-review
In this work, the authors reported a comparison study of two different types of 
fiducial markers for robotic radiosurgery. In this study, 15 patients have been 
recruited, in which 48 gold markers were placed (32 Grain shaped markers 
and 16 Gold Anchor). All these patients except one were scanned with CT for 
visualization and identification of these markers. The data of these patients 
were analyzed and reported in this work. The work intended to address an 
interesting clinical issue.
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